{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:00:18Z","timestamp":1791572418810,"version":"4.3.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA197098-01"],"award-info":[{"award-number":["R01CA197098-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX005260-01"],"award-info":[{"award-number":["BX005260-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ymthe.2022.07.015","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T12:49:41Z","timestamp":1659790181000},"page":"3450-3461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics"],"prefix":"10.1016","volume":"30","author":[{"given":"John G.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Ram","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfang","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.07.015_bib1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.07.015_bib2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","article-title":"Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans","volume":"75","author":"Wightman","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.07.015_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs\u2014microRNAs with a role in cancer","volume":"6","author":"Esquela-Kerscher","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2022.07.015_bib4","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.07.015_bib5","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.07.015_bib6","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-07-1083","article-title":"The let-7 microRNA represses cell proliferation pathways in human cells","volume":"67","author":"Johnson","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.07.015_bib7","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1038\/cddis.2013.193","article-title":"miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer","volume":"4","author":"Karaayvaz","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2022.07.015_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/1541-7786.MCR-10-0497","article-title":"miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1\/VEGFR1","volume":"9","author":"Roybal","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.07.015_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000113489","article-title":"Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer","volume":"72","author":"Slaby","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.ymthe.2022.07.015_bib10","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.1158\/1078-0432.CCR-08-1422","article-title":"miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit","volume":"14","author":"Song","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.07.015_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1476-4598-9-96","article-title":"Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells","volume":"9","author":"Song","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2022.07.015_bib12","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1158\/1078-0432.CCR-05-1853","article-title":"Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer","volume":"12","author":"Xi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.07.015_bib13","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/onc.2012.167","article-title":"Inhibition of autophagy and tumor growth in colon cancer by miR-502","volume":"32","author":"Zhai","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2022.07.015_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.drudis.2016.10.014","article-title":"miRNA nanotherapeutics for cancer","volume":"22","author":"Ganju","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2022.07.015_bib15","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jconrel.2013.09.015","article-title":"Progress in microRNA delivery","volume":"172","author":"Zhang","year":"2013","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2022.07.015_bib16","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","article-title":"The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation","volume":"31","author":"Kedmi","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2022.07.015_bib17","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3390\/molecules23102564","article-title":"Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides","volume":"23","author":"Wang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2022.07.015_bib18","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2022.07.015_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2022.07.015_bib21","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti\u2013polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib22","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1126\/science.1102218","article-title":"Microbial factor-mediated development in a host-bacterial mutualism","volume":"306","author":"Koropatnick","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.07.015_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2022.07.015_bib24","first-page":"23","article-title":"Cytotoxic impacts of linear and branched polyethylenimine nanostructures in a431 cells","volume":"1","author":"Kafil","year":"2011","journal-title":"Bioimpacts."},{"key":"10.1016\/j.ymthe.2022.07.015_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.07.015_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/bi00700a012","article-title":"Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate","volume":"13","author":"Santi","year":"1974","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymthe.2022.07.015_bib28","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.18632\/oncotarget.23414","article-title":"Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1","volume":"9","author":"Fesler","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2022.07.015_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.omtn.2019.11.010","article-title":"Functional significance and therapeutic potential of miR-15a mimic in pancreatic Ductal adenocarcinoma","volume":"19","author":"Guo","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2022.07.015_bib30","doi-asserted-by":"crossref","first-page":"8887","DOI":"10.18632\/oncotarget.22322","article-title":"Development of novel miR-129 mimics with enhanced efficacy to eliminate chemoresistant colon cancer stem cells","volume":"9","author":"Wu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2022.07.015_bib31","doi-asserted-by":"crossref","first-page":"E2209","DOI":"10.3390\/cancers12082209","article-title":"Therapeutic potential of Chemically modified miR-489 in Triple-negative breast cancers","volume":"12","author":"Soung","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2022.07.015_bib32","doi-asserted-by":"crossref","first-page":"19735","DOI":"10.18632\/oncotarget.3771","article-title":"Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy","volume":"6","author":"Zhai","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2022.07.015_bib33","first-page":"9413","article-title":"miR-506 in patients with chronic myeloid leukemia and its effect on apoptosis of K562 cells","volume":"13","author":"Chen","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ymthe.2022.07.015_bib34","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2016.90","article-title":"Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1\/Akt\/NF-kappaB signaling","volume":"35","author":"Li","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2022.07.015_bib35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1101\/gad.233585.113","article-title":"A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression","volume":"28","author":"Okada","year":"2014","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2022.07.015_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4161\/rna.5.3.6558","article-title":"The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis","volume":"5","author":"Korpal","year":"2008","journal-title":"RNA Biol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib37","first-page":"1481","article-title":"miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer","volume":"7","author":"Fesler","year":"2014","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.ymthe.2022.07.015_bib38","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2022.07.015_bib39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.gene.2018.09.011","article-title":"Hyperoside and let-7a-5p synergistically inhibits lung cancer cell proliferation via inducing G1\/S phase arrest","volume":"679","author":"Li","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2022.07.015_bib40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1089\/dna.2013.2179","article-title":"Let-7a functions as a tumor suppressor in Ewing's sarcoma cell lines partly by targeting cyclin-dependent kinase 6","volume":"33","author":"Zhang","year":"2014","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib41","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.febslet.2014.02.054","article-title":"MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer","volume":"588","author":"Qiu","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymthe.2022.07.015_bib42","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10120-019-01018-7","article-title":"CircDUSP16 promotes the tumorigenesis and invasion of gastric cancer by sponging miR-145-5p","volume":"23","author":"Zhang","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ymthe.2022.07.015_bib43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2022.07.015_bib44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib45","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2013 from liposomes to mRNA vaccine delivery, a Landscape of Research Diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2022.07.015_bib46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2022.07.015_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/intimm\/dxt040","article-title":"Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in\u00a0vivo and in\u00a0vitro","volume":"26","author":"Broering","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib48","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.4161\/cc.9.9.11535","article-title":"miR-129 regulates cell proliferation by downregulating Cdk6 expression","volume":"9","author":"Wu","year":"2010","journal-title":"Cell cycle"},{"key":"10.1016\/j.ymthe.2022.07.015_bib49","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1002\/jcp.26383","article-title":"LncRNA MALAT1 induces colon cancer development by regulating miR-129-5p\/HMGB1 axis","volume":"233","author":"Wu","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib50","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","article-title":"RAS is regulated by the let-7 microRNA family","volume":"120","author":"Johnson","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.07.015_bib51","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2007.10.054","article-title":"let-7 regulates self renewal and tumorigenicity of breast cancer cells","volume":"131","author":"Yu","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.07.015_bib52","doi-asserted-by":"crossref","first-page":"e6816","DOI":"10.1371\/journal.pone.0006816","article-title":"MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells","volume":"4","author":"Ji","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.07.015_bib53","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2007.05.010","article-title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis","volume":"26","author":"Chang","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2022.07.015_bib54","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2007.05.017","article-title":"Transcriptional activation of miR-34a contributes to p53-mediated apoptosis","volume":"26","author":"Raver-Shapira","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2022.07.015_bib55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.07.015_bib56","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.4161\/cc.6.13.4436","article-title":"Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest","volume":"6","author":"Tarasov","year":"2007","journal-title":"Cell cycle"},{"key":"10.1016\/j.ymthe.2022.07.015_bib57","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.ejca.2009.04.039","article-title":"Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation","volume":"45","author":"Cho","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2022.07.015_bib58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4161\/rna.8.1.14259","article-title":"MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1","volume":"8","author":"Cho","year":"2011","journal-title":"RNA Biol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib59","doi-asserted-by":"crossref","first-page":"e3101","DOI":"10.1038\/cddis.2017.493","article-title":"miR-143 and miR-145 inhibit gastric cancer cell migration and metastasis by suppressing MYO6","volume":"8","author":"Lei","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2022.07.015_bib60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopha.2014.12.019","article-title":"Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer","volume":"69","author":"Shen","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2022.07.015_bib61","doi-asserted-by":"crossref","first-page":"e114420","DOI":"10.1371\/journal.pone.0114420","article-title":"MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer","volume":"9","author":"Su","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.07.015_bib62","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s13277-014-2849-1","article-title":"miR-194 targets RBX1 gene to modulate proliferation and migration of gastric cancer cells","volume":"36","author":"Chen","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yexcr.2019.03.007","article-title":"miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway","volume":"378","author":"Ran","year":"2019","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ymthe.2022.07.015_bib64","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1245\/s10434-011-1999-2","article-title":"Inverse association between miR-194 expression and tumor invasion in gastric cancer","volume":"19","author":"Song","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib65","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib66","doi-asserted-by":"crossref","first-page":"14910","DOI":"10.1074\/jbc.C800074200","article-title":"The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2","volume":"283","author":"Korpal","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.07.015_bib67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-14-85","article-title":"MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell","volume":"14","author":"Lu","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ymthe.2022.07.015_bib68","doi-asserted-by":"crossref","first-page":"12215","DOI":"10.2147\/CMAR.S279978","article-title":"MicroRNA-200c nanoparticles Sensitized gastric cancer cells to Radiotherapy by regulating PD-L1 expression and EMT","volume":"12","author":"Qian","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ymthe.2022.07.015_bib69","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1158\/1535-7163.MCT-10-0061","article-title":"miR-192\/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation","volume":"9","author":"Boni","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2022.07.015_bib70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.canlet.2013.08.033","article-title":"MiR-215 modulates gastric cancer cell proliferation by targeting RB1","volume":"342","author":"Deng","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2022.07.015_bib71","doi-asserted-by":"crossref","first-page":"e64273","DOI":"10.1371\/journal.pone.0064273","article-title":"miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines","volume":"8","author":"Arora","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.07.015_bib72","doi-asserted-by":"crossref","first-page":"32586","DOI":"10.18632\/oncotarget.5309","article-title":"MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2022.07.015_bib73","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1002\/jcp.27525","article-title":"miR-145-5p affects the differentiation of gastric cancer by targeting KLF5 directly","volume":"234","author":"Zhou","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib74","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.18632\/oncotarget.6821","article-title":"MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer","volume":"7","author":"Tang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2022.07.015_bib75","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/carcin\/bgr035","article-title":"Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C","volume":"32","author":"Yang","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ymthe.2022.07.015_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-07-0573","article-title":"MicroRNAs modulate the chemosensitivity of tumor cells","volume":"7","author":"Blower","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2022.07.015_bib77","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3389\/fonc.2019.00808","article-title":"Exogenous let-7a-5p induces A549 lung cancer cell death through BCL2L1-mediated PI3K\u03b3 signaling pathway","volume":"9","author":"Duan","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2022.07.015_bib78","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cbic.200301023","article-title":"Fluorine in medicinal chemistry","volume":"5","author":"B\u00f6hm","year":"2004","journal-title":"Chembiochem."},{"key":"10.1016\/j.ymthe.2022.07.015_bib79","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1039\/B610213C","article-title":"Fluorine in medicinal chemistry","volume":"37","author":"Purser","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ymthe.2022.07.015_bib80","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1093\/nar\/gkv298","article-title":"2\u2032-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF","volume":"43","author":"Shen","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2022.07.015_bib81","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/nar\/gkh516","article-title":"2\u2032-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in\u00a0vitro","volume":"32","author":"Yoo","year":"2004","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622004361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622004361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:04:34Z","timestamp":1761501874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622004361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":81,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1525001622004361"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.07.015","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.23.497408","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}